(3E)-5-bromo-2-chloropenta-1,3-diene

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 乙烯基卤化物
• 英文名称: (3E)-5-bromo-2-chloropenta-1,3-diene
• 化学式: C₅H₆BrCl
• 分子量: 181.46
• InChiKey: QHVILMVSSMUBOB-NSCUHMNNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

文献信息

• [EN] POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)<br/>[FR] INHIBITEURS POLYCYCLIQUES DE KINASE CYCLINE-DÉPENDANTE 7 (CDK7)
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2015058140A1

  公开（公告）日：2015-04-23

  The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing' s sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7), cyclin-dependent kinase 12 (CDK12), or cyclin-dependent kinase 13 (CDK13)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

  本发明提供了一种新型化合物的公式（I），以及其药用可接受的盐、溶剂合物、水合物、多晶形态、共晶体、互变异构体、立体异构体、同位素标记衍生物、前药和其组合物。还提供了涉及创新化合物或组合物的方法和试剂盒，用于治疗或预防增殖性疾病（例如，癌症（例如，白血病、淋巴瘤、黑色素瘤、多发性骨髓瘤、乳腺癌、尤因氏肉瘤、骨肉瘤、脑癌、神经母细胞瘤、肺癌）、良性肿瘤、血管生成、炎症性疾病、自身炎症性疾病和自身免疫疾病）的方法和试剂盒。使用本发明的化合物或组合物治疗患有增殖性疾病的对象可能抑制激酶的异常活性，如细胞周期依赖性激酶（CDK）（例如，细胞周期依赖性激酶7（CDK7）、细胞周期依赖性激酶12（CDK12）或细胞周期依赖性激酶13（CDK13）），从而在对象中诱导细胞凋亡和/或抑制转录。
• [EN] INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)<br/>[FR] INHIBITEURS DE LA KINASE CYCLINE-DÉPENDANTE 7 (CDK7)
  申请人：SYROS PHARMACEUTICALS INC

  公开号：WO2015154038A1

  公开（公告）日：2015-10-08

  The present invention provides novel compounds of Formula (lc) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

  本发明提供了公式（lc）的新化合物和药学上可接受的盐、溶剂合物、水合物、互变异构体、立体异构体、同位素标记衍生物和其组合物。还提供了涉及这些化合物或组合物的方法和试剂盒，用于治疗或预防受试者的增殖性疾病（例如癌症（例如白血病、黑色素瘤、多发性骨髓瘤）、良性肿瘤、血管生成、炎症性疾病、自身炎症性疾病和自身免疫性疾病）。使用本发明的化合物或组合物治疗患有增殖性疾病的受试者，可以抑制细胞周期依赖性激酶7（CDK7）的异常活性，从而在受试者中诱导细胞凋亡和/或抑制转录。
• PROCESS FOR THE PREPARATION OF QUINAZOLINYL DERIVATIVES
  申请人：Hetero Labs Ltd.

  公开号：EP3567038A1

  公开（公告）日：2019-11-13

  The present invention relates to processes for the preparation of afatinib base and afatinib dimaleate.

  本发明涉及阿法替尼碱基和阿法替尼二马来酸盐的制备工艺。
• [EN] BICYCLIC COMPOUND FUNCTIONING AS TYROSINE KINASE INHIBITOR<br/>[FR] COMPOSÉ BICYCLIQUE FONCTIONNANT EN TANT QU'INHIBITEUR DE TYROSINE KINASE
  申请人：KBP BIOSCIENCES CO LTD

  公开号：WO2014089913A1

  公开（公告）日：2014-06-19

  本发明涉及通式（I）所示的化合物，制备所述化合物的方法，含有所述化合物的药物组合物，以及所述化合物在制备用于预防和/或治疗B细胞相关的血癌、炎性以及自身免疫性疾病的药物中的应用，其中X、W、环A、环B、L1、L2、R1、R2、R３、﹉、a、b、c、d、e、p和q如说明书中所定义。
• [EN] HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES<br/>[FR] COMPOSÉS HÉTÉROAROMATIQUES UTILES DANS LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
  申请人：SYROS PHARMACEUTICALS INC

  公开号：WO2015058126A1

  公开（公告）日：2015-04-23

  The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.